• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kenvue Introduces Patented Micro-Peptide Technology with Neutrogena® Collagen Bank™ Launch

    8/15/24 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email

    New Product Line Features Two Moisturizers Designed to Defend and Support the Skin's Natural Collagen

    SKILLMAN, N.J., Aug. 15, 2024 /PRNewswire/ -- Kenvue Inc. (NYSE:KVUE) ("Kenvue" or the "Company"), the world's largest pure-play consumer health company by revenue, is launching Neutrogena®1 Collagen Bank™ featuring the Company's patented micro-peptide technology. The launch propels Neutrogena®, the #1 Face Care Brand2,  into the pre-aging category and is poised to meet the needs of Gen Z, a new generation of consumers, seeking ways to proactively prevent their skin from aging.

    According to a 2023 Mintel Facial Skincare study, 58 percent of Gen Z is worried about aging concerns beginning at age 23. With collagen being a vital protein responsible for keeping skin looking plump, and the body naturally losing up to one percent of collagen each year starting in its twenties3, the oldest Gen Z consumers are reaching a pivotal collagen-loss point. Neutrogena® Collagen Bank™ offers an affordable and accessible way to invest in skin for the long-term.

    Neutrogena® Collagen Bank™ harnesses the power of a patented micro-peptide technology two times smaller than the leading anti-aging peptides on the market to penetrate more than 10 layers under the surface of the skin. Comparatively, the leading anti-aging peptides are too big to penetrate and sit on the surface of the skin. The Company's proprietary technology, developed with dermatologists, targets five markers critical for preserving skin's firming support matrix: elastin, pro-collagen, hyaluronic acid, fibronectin and decorin. 

    "Collagen Bank™ is a cutting-edge solution for a generation of consumers looking to take a preventative approach to skincare," said Adam Ricciardone, Global Head of R&D, Skin Health & Beauty at Kenvue4. "We know that Millennials and Gen Z are trying a lot of different approaches to their skincare. Our scientifically proven formulation addresses their concerns and prioritizes long-term skin health at the same time."

    The new collection offers two dermatologist-tested formulations designed for all skin tones and types and meant for daily use, even on sensitive skin. Each formula provides different added benefits:

    • Neutrogena® Collagen Bank™ Moisturizer includes bakuchiol, a gentle plant-based alternative to retinol, that helps to defend against collagen damaging aggressors and fights visible signs of early skin aging.
    • Neutrogena® Collagen Bank™ Broad Spectrum SPF 30 Moisturizer defends against the number one collagen depleting aggressor, the sun.

    When used together, the products are clinically proven to work on five early signs of collagen decline and reduce the look of fine lines and wrinkles, leaving skin looking plumper.5

    To reach digitally native Gen Z, Neutrogena® exclusively launched the collection on TikTok Shop in July, prior to rolling out across traditional retailers like Amazon, UTLA Beauty, Walmart, Target, and more. While in-office collagen-stimulating procedures and other products come with high price tags, Neutrogena® Collagen Bank™, offers a more accessible solution for those looking to help prevent skin-aging without breaking the bank. The Neutrogena® Collagen Bank™ line is available online and at mass retailers nationwide now. To learn more about Neutrogena® Collagen Bank™, visit Neutrogena.com or follow Neutrogena® on Instagram and TikTok at @neutrogena_us.

    About Kenvue

    Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

    About NEUTROGENA®

    For over 90 years, NEUTROGENA® has made sophisticated science simple, developing solutions for everyday skincare that balance clinical efficacy with elegant aesthetics. From science-backed innovation to accessible education, we are driven by a mission to democratize skin health. Our products address skin needs across ages, skin types and tones.

    Cautions Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of Neutrogena® Collagen Bank™. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue Inc. and its affiliates.

    A list and descriptions of risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.

    1

    Neutrogena is a brand of Johnson & Johnson Consumer Inc., a subsidiary of Kenvue

    2

    Based on Nielsen sales data for the 52 weeks ending 1/27/24

    3

    Mintel Facial Skincare 2023

    4

    Adam Ricciardone is an employee of Johnson & Johnson Consumer Inc., a subsidiary of Kenvue

    5

    *With daily use of SPF Moisturizer in the AM and Moisturizer in the PM over 12 weeks.

    Reference: 1. Data on file, Johnson & Johnson Consumer Inc.

     

    Contact: [email protected]

    Kenvue Introduces Patented Micro-Peptide Technology with Neutrogena Collagen Bank™ Moisturizers

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kenvue-introduces-patented-micro-peptide-technology-with-neutrogena-collagen-bank-launch-302222859.html

    SOURCE Neutrogena

    Get the next $KVUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    1/30/2026$18.00Buy → Hold
    Jefferies
    10/29/2025$15.00Buy → Hold
    Canaccord Genuity
    9/26/2025$22.00Neutral → Buy
    Rothschild & Co Redburn
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    More analyst ratings

    $KVUE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

    SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

    2/17/26 10:26:21 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Inc. filed SEC Form 8-K: Leadership Update

    8-K - Kenvue Inc. (0001944048) (Filer)

    2/12/26 4:07:23 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Kenvue Inc. (0001944048) (Filer)

    1/29/26 4:30:38 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Officer Alvarado Luani exercised 85,534 shares at a strike of $13.76 and covered exercise/tax liability with 71,581 shares, increasing direct ownership by 43% to 46,602 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    2/10/26 4:19:38 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 3 filed by new insider Curado Gomes De Lemos Leonardo

    3 - Kenvue Inc. (0001944048) (Issuer)

    1/12/26 5:16:49 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 4 filed by Chief Financial Officer Banati Amit

    4 - Kenvue Inc. (0001944048) (Issuer)

    1/6/26 4:39:35 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Jeffrey C bought $110,986,526 worth of shares (6,377,694 units at $17.40) (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/15/25 4:00:25 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kenvue downgraded by Jefferies with a new price target

    Jefferies downgraded Kenvue from Buy to Hold and set a new price target of $18.00

    1/30/26 6:43:10 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Kenvue from Buy to Hold and set a new price target of $15.00

    10/29/25 7:19:36 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Kenvue from Neutral to Buy and set a new price target of $22.00

    9/26/25 8:00:14 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue

    Key Milestone in Creating a Global Health and Wellness Leader Transaction Expected to Close in the Second Half of 2026 DALLAS and SUMMIT, N.J., Jan. 29, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ:KMB) and Kenvue Inc. (NYSE:KVUE) today announced that Kimberly-Clark and Kenvue shareholders voted overwhelmingly to approve all of the proposals necessary for Kimberly-Clark to complete its acquisition of Kenvue at their respective Special Meetings of Stockholders held today. "We are grateful to Kimberly-Clark shareholders who voted resoundingly in support of our combina

    1/29/26 9:27:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on February 25, 2026, to shareholders of record as of the close of business on February 11, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    1/28/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    View All

    Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

    Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

    7/14/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Debuts on Fortune 500 List

    Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

    6/2/25 6:15:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Announces Chief Financial Officer Transition

    Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    View All

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on February 25, 2026, to shareholders of record as of the close of business on February 11, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    1/28/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader

    Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Will Provide Preferred Solutions Through Every Stage of Life Applies Kimberly-Clark's Proven Commercial Execution Playbook to Create a Best-in-Class Consumer-Driven Company Accelerates Kenvue's Premier Consumer Health Portfolio and Strong Science-Backed Innovation, Supported by Talented Kenvue Team Enhances Investment in Marketing, Innovation and R&D Capabilities to Strengthen Combined Company's Unique Advantages Total Anticipated Run-Rate Synergies of $2.1 Billion; Expected to Be Accretive to Kimberly-Clark's Adjusted EPS By Year 2 Delivers Immediate Upfront Value to K

    11/3/25 6:30:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    10/16/24 10:07:52 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary